Immix Biopharma, Inc.
IMMX
$2.03
-$0.065-3.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 58.80% | 21.99% | 63.97% | 94.85% | 48.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.23% | 63.47% | 26.39% | 121.76% | 41.67% |
| Operating Income | 7.23% | -63.47% | -26.39% | -121.76% | -41.67% |
| Income Before Tax | 6.72% | -64.59% | -22.38% | -113.49% | -35.65% |
| Income Tax Expenses | 33.33% | 63.24% | 63.49% | 69.23% | 52.83% |
| Earnings from Continuing Operations | 6.66% | -64.58% | -22.45% | -113.41% | -35.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -- | -41.36% | 291.85% | -- |
| Net Income | 5.45% | -67.01% | -22.84% | -112.08% | -33.94% |
| EBIT | 7.23% | -63.47% | -26.39% | -121.76% | -41.67% |
| EBITDA | 7.56% | -63.40% | -26.30% | -121.69% | -41.61% |
| EPS Basic | 30.34% | -5.47% | 35.83% | -25.78% | 14.43% |
| Normalized Basic EPS | 29.85% | -6.39% | 35.72% | -25.27% | 15.13% |
| EPS Diluted | 30.34% | -5.47% | 35.83% | -25.78% | 14.43% |
| Normalized Diluted EPS | 29.85% | -6.39% | 35.72% | -25.27% | 15.13% |
| Average Basic Shares Outstanding | 35.73% | 58.38% | 91.40% | 68.65% | 56.57% |
| Average Diluted Shares Outstanding | 35.73% | 58.38% | 91.40% | 68.65% | 56.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |